Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Minority Health (CHD-MH) (U54 Clinical Trial Optional)
Posted by National Institutes of Health
Opportunity snapshot. This Grants.gov announcement — Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Minority Health (CHD-MH) (U54 Clinical Trial Optional) — is cataloged under number RFA-CA-24-020 and tied to CFDA assistance listing 93.395, posted by National Institutes of Health. Grants.gov currently shows the opportunity as closed, first posted on March 27, 2024. The funding category is Discretionary, delivered as a cooperative agreement.
Award economics. The award range on file is Up to $1,600,000. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity closed on September 26, 2024. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully — federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed — it helps clarify scope and scoring priorities.
Award Range
Up to $1,600,000
Close Date
September 26, 2024
Posted
March 27, 2024
Instrument
Cooperative Agreement
Description
The purpose of the U54 CHD-MH SPORE Program is to fund a network of multi-disciplinary, multi-institutional translational research SPOREs uniquely focused on 1) health disparities and/or minority health research and 2) the development of novel-cancer relevant interventions in underserved populations with cancer or at risk for cancer.
Eligibility
00;01;02;04;05;06;07;08;11;12;13;20;22;23;25
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Parent Grant Program
Cancer Treatment Research
National Institutes of Health
Agency Contact
NIH Grants Information<br/>grantsinfo@nih.gov
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from National Institutes of Health
Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)
Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)
Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed)
Research Grants in Clinical Informatics (R01 Clinical Trial Optional)
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology — how this data is sourced, computed, and verified.
Related
| Publisher | Kiznis Studio |
| Sources | Public official public datasets |